Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Other: low fat meal
Other: high fat meal

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273427

Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Asasantin®

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02273479

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 11054 CL
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02273401

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation II
Drug: Asasantin ER, new formulation I
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02273518

Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Desipramine tablet
Drug: Crobenetine infusion
Drug: Placebo infusion

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273466

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Asasantin ER - commercial formulation
Drug: Asasantin ER (new formulation - low)
Drug: Asasantin ER (new formulation - high)
Drug: Asasantin ER (new formulation - medium)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273544

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 695502
Drug: Avastin

First Posted Date: 2014-10-23

Last Posted Date: 2020-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 671

Registration Number: NCT02272413

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Southern California Oncology Research Alliance, Los Angeles, California, United States
🇺🇦
CI Zapor Reg Cl Oncological Dispensary of ZRC, Zhaporizhzhia, Zhaporizhzhia, Ukraine

and more 186 locations

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BIIL 284 BS, low dose
Drug: BIIL 284 BS, high dose
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02269189

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam, tablet
Drug: Crobenetine, i.v. infusion
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02269202

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIII 890 CL
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 73

Registration Number: NCT02269215

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy